Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-07-15
2011-11-29
Stockton, Laura L. (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C548S305100, C548S306100, C546S199000, C546S273400, C514S322000, C514S338000, C514S394000
Reexamination Certificate
active
08067613
ABSTRACT:
Compounds which inhibit the activity of poly(ADP-ribose)polymerase (PARP), compositions containing the compounds and methods of treating diseases using them are disclosed.
REFERENCES:
patent: 3864385 (1975-02-01), Feit et al.
patent: 4093726 (1978-06-01), Winn et al.
patent: 6372736 (2002-04-01), Kemp et al.
patent: 6448271 (2002-09-01), Lubisch et al.
patent: 6509365 (2003-01-01), Lubisch et al.
patent: 6696437 (2004-02-01), Lubisch et al.
patent: 6737421 (2004-05-01), Lubsich et al.
patent: 7166292 (2007-01-01), Isele et al.
patent: RE39608 (2007-05-01), Lubisch et
patent: 7462724 (2008-12-01), Penning et al.
patent: 7550603 (2009-06-01), Zhu et al.
patent: 2003/0100582 (2003-05-01), Sircar et al.
patent: 2005/0159427 (2005-07-01), Bruncko et al.
patent: 2006/0229289 (2006-10-01), Zhu et al.
patent: 2006/0229351 (2006-10-01), Zhu et al.
patent: 2007/0179136 (2007-08-01), Penning et al.
patent: 2007/0259937 (2007-11-01), Giranda et al.
patent: 2007/0265324 (2007-11-01), Wernet et al.
patent: 3522230 (1987-01-01), None
patent: 3830060 (1990-03-01), None
patent: 19916460 (2000-10-01), None
patent: 10021468 (2001-11-01), None
patent: 19920936 (2001-11-01), None
patent: 1354554 (1974-06-01), None
patent: 2002-141067 (2002-05-01), None
patent: 97/04771 (1997-02-01), None
patent: 98/39343 (1998-09-01), None
patent: 00/29384 (2000-05-01), None
patent: 00/32579 (2000-06-01), None
patent: 00/26192 (2000-11-01), None
patent: 01/21615 (2001-03-01), None
patent: 01/21634 (2001-03-01), None
patent: 01/82877 (2001-11-01), None
patent: 02/068407 (2002-09-01), None
patent: 03/002698 (2003-01-01), None
patent: 03/094861 (2003-11-01), None
patent: 03/106430 (2003-12-01), None
patent: 2004/054515 (2004-07-01), None
patent: 2004/065370 (2004-08-01), None
patent: 2004/096793 (2004-11-01), None
patent: 2004/098494 (2004-11-01), None
patent: 2007/059230 (2007-05-01), None
Amundson, et al., “An Informatics Approach Identifying Markers of Chemosensitivity in Human Cancer Cell Lines”, Cancer Res, 60(21), 6101-6110 (2000).
Burkart, et al., “Mice lacking the poly(ADP-ribose)polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin”, Nature Medicine, 5(3), 314-319 (1999).
Chen, et al., “Potentiation of the antitumor activity of cisplation in mice by 3-aminobenzamide and nicotinamide”, Cancer Chemotherapy and Pharmacology, 22,303-307 (1988).
Cuzzocrea, et al., “Protective effects of 3-Aminobenzamide, an inhibitor of poly(ADP-ribose) synthase in a carrrageenan-induced model of local inflammation”, Eur J Pharmacol, 342, 67-76 (1998).
Ehrlich, et al., “Inhibition of the induction of collagenase by interleukin-1b in cultured rabbit synovial fibroblasts after treatment with the poly(ADP-ribose)-polymerase inhibitoro 3-aminobenzamide”, Rheumatol Int, 15, 171-172 (1995).
Holzelova, et al., “Autoimmune Lymphoproliferative Syndrome with Somatic Fas Mutations”, N Engl J Med, 31(14), 1409-1418 (2004).
IUPAC 1974 Recommendations for Sec E, Fundamental Stereochemistry, Pure Appl Chem,45,13-30 (1976).
Kroger et al, “Synergistic effects of thalidomide and poly(ADP-ribose) polumerase inhibition on type II collagen-induced arthritis in mice”, Inflammation, 20, 203-215 (1996).
Puck,et al., “Immune Disorders Caused by Defects in the Caspase Cascade”, Current Allergy and Asthma Reports, 3, 378-384 (2003).
Rengan, et al., “Actin cytoskeletal function is spared, but apoptosis is increased, in WAS patient Hematopoietic cells”, Blood, 95(4), 1283-1292 (2000).
Shimazaki, et al., “Evalluation of apoptosis as a prognostic factor in Myelodysplastic syndromes”, British Journal of Haematology, 110(3), 584-590 (2000).
Szabo, et al., Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of pyly (ADP-ribose) synthase, Proc Natl Acad Sci USA, 95(7), 3867-3872 (1998).
Thiemermann, et al., “Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle”, PNAS, 94, 679-683 (1997).
Weltin, et al., “Immunosuppressive activities of 6(5H)-phenanthridinone a new poly(ADP-ribose)Polymerase inhibitor”, Int J Immunopharmacol, 17(4), 265-271 (1995).
Co-Pending U.S. Appl. No. 09/830,992, filed May 2001.
Co-Pending U.S. Appl. No. 10/935,683, filed Sep. 2004.
Co-Pending U.S. Appl. No. 11/401,635, filed Apr. 2006.
Co-Pending U.S. Appl. No. 11/536,994, filed Sep. 2006.
Co-Pending U.S. Appl. No. 11/560,166, filed Nov. 2006.
Co-Pending U.S. Appl. No. 11/743,200, filed May 2007.
Search Report No. 20030374, Jun. 13, 2003.
Search Report No. 20030487, Sep. 19, 2003.
Search Report No. 20050150, Apr. 22, 2005.
Search Report No. 20050207, May 27, 2005.
Alexy, et al., “Inhibition of ADP-Evoked Platelet Aggregation by Selected Poly(ADP-Ribose) Polymerase Inhibitors”, Journal Cardiovascular Pharmacol 43(3), 423-431 (2004).
Gilchrist, et al., “Cyclisation of ortho-Substituted N-Arylben zimidoyl Nitrenes. Part 2. Preferential Cyclisations at an ortho-Position Bearin a Methoxycarbonyl Group”, Journal of Chem. Society, Perkin Transactions 1, GB, Chemical Society, Letchworth, 2303-2307 (1979).
Griffin, et al., “Resistance modifying agents 3. Novel benzimidazole and quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase.” Pharmaceutical Sciences, 2(1), 43-47 (1996).
Kröger, H., et al., “Synergistic Effects of Thalidomide and Poly(ADP-Ribose) Polymerase Inhibition of Type II Collagen-Induced Arthritis in Mice”, Inflammation, 20(2):203-215 (1996).
White, et al., “Potentiation of cytotoxic drug activity in human tumore cell lines, by amine-substituted 2-arylbenzimidazol-4carboxamide PARP-1 inhibitors”, Bioorganic & Medicinal Chemistry Letters, 14(10), 2433-2437 (2004).
Co-pending U.S. Appl. No. 11/623,996, filed Jan. 2007.
Co-pending U.S. Appl. No. 11/830,318, filed Jul. 2007.
Co-pending U.S. Appl. No. 11/970,828, filed Jan. 2008.
Co-pending U.S. Appl. No. 12/058,478, filed Mar. 2008.
Co-pending U.S. Appl. No. 12/116,823, filed May 2008.
Co-pending U.S. Appl. No. 12/117,452, filed May 2008.
Co-pending U.S. Appl. No. 12/413,834, filed Mar. 2009.
Gandhi Virajkumar B.
Giranda Vincent L.
Gong Jianchun
Penning Thomas D
Zhu Gui-Dong
Abbott Laboratories
Polster Rachel A.
Steele Susan L.
Stockton Laura L.
LandOfFree
Benzimidazole poly(ADP ribose)polymerase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzimidazole poly(ADP ribose)polymerase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzimidazole poly(ADP ribose)polymerase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4283955